NCT05870423 (PRRT-PARPi) is a Phase 1 clinical trial of olaparib in Neuroendocrine Tumors, sponsored by Erasmus Medical Center.

Who is sponsoring NCT05870423?

NCT05870423 is sponsored by Erasmus Medical Center.

What drugs are being tested in NCT05870423?

Interventions in NCT05870423: olaparib.

What condition does NCT05870423 study?

NCT05870423 studies Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy.

Is NCT05870423 still recruiting?

NCT05870423 is currently recruiting now. Last updated 5 June 2025.

Last reviewed 2025-06-05 · How we verify

NCT05870423: PRRT-PARPi

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Recruiting now Phase 1 Last updated 5 June 2025

What this trial tests

Phase 1 trial testing olaparib in Neuroendocrine Tumors in 24 participants. Currently enrolling.

Timeline

1 June 2022

Primary endpoint
1 January 2027

1 January 2027

Quick facts

Lead sponsor	Erasmus Medical Center
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 June 2022
Primary completion	1 January 2027
Estimated completion	1 January 2027
Sites	1 location across Netherlands

Drugs / interventions tested

olaparib (olaparib) — full drug profile →

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Peptide Receptor Radionuclide Therapy — all drugs for Peptide Receptor Radionuclide Therapy →

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Neuroendocrine Tumors or Peptide Receptor Radionuclide Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced gastroenteropancreatic NET (GEP NET), progressive after PRRT. As secondary objectives, efficacy, pharmacokinetics and biomarker response will be investigated.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.
di Santo G, Santo G, Sviridenko A, Virgolini I. · · 2024 · cited 24× · PMID 38250038 · DOI 10.7150/thno.91268
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.
Di Franco M, Zanoni L, Fortunati E, Fanti S, et al · · 2024 · cited 13× · PMID 38581469 · DOI 10.1007/s11912-024-01526-5
Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment.
Tan B, Zhang B, Chen H. · · 2024 · cited 10× · PMID 39411312 · DOI 10.3389/fendo.2024.1424839
Combining [<sup>177</sup>Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer.
Rauch H, Kitzberger C, Janghu K, Hawarihewa P, et al · · 2024 · cited 8× · PMID 39023784 · DOI 10.1007/s00259-024-06844-1
Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.
Richter S, Steenblock C, Fischer A, Lemm S, et al · · 2024 · cited 8× · PMID 38164150 · DOI 10.7150/thno.87345
Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.
Virgolini IJ, Di Santo G, Santo G. · · 2026 · cited 2× · PMID 41689648 · DOI 10.1007/s00259-025-07750-w
Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.
Xue E, Bracken-Clarke D, Krause H, Adeyelu T, et al · · 2024 · cited 2× · PMID 39682120 · DOI 10.3390/cancers16233931
Atypical R-loops in cancer: decoding molecular chaos for therapeutic gain.
Sun Y, Wang S, Ge N, Guo J, et al · · 2025 · cited 1× · PMID 40813661 · DOI 10.1186/s12967-025-06929-x

Verify or expand the search:

Other trials of olaparib

Trials testing the same drug.

NCT05209529 — Chemo-free BRCA-targeted Neoadjuvant Strategy · Phase 2 · withdrawn
NCT05457257 — Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Pr · Phase 4 · completed
NCT05158062 — Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian · Phase 2 · unknown
NCT05171816 — Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (Ch · Phase 3 · active not recruiting
NCT04483544 — Pembrolizumab and Olaparib in Cervical Cancer Patients · Phase 2 · terminated

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other Erasmus Medical Center trials

Trials by the same sponsor.

NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05870423 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
Last refreshed: 5 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing